Holen Sie sich die Stockscreener-App
151.00
0.15%
-0.225
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$151.22
Offen:
$149.23
24-Stunden-Volumen:
5.98M
Relative Volume:
0.84
Marktkapitalisierung:
$187.23B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
20.55
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+3.65%
1M Leistung:
+11.64%
6M Leistung:
+1.87%
1J Leistung:
+33.90%
1-Tages-Spanne:
$149.23
$151.19
1-Wochen-Bereich:
$143.18
$152.55
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
151.00 | 177.86B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.
Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Could Gilead Sciences (NASDAQ:GILD) Remain a Nasdaq Focus? - Kalkine Media
Amundi Has $1.23 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Saudi Central Bank Acquires 41,091 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Strategically Prepares for HIV Market Changes - Intellectia AI
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative? - Yahoo Finance
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? - 24/7 Wall St.
Q&A: Gilead's Betty Chiang on what Bixlenvo means for HIV patients on complex regimens - The Pharma Letter
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
TD Waterhouse Canada Inc. Sells 70,572 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
AXQ Capital LP Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences (GILD) Chairman & CEO Daniel O'Day Sells 15,000 Shares - GuruFocus
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report? - Yahoo Finance
Gilead Sciences Q1 EPS Estimate Raised by Zacks Research - MarketBeat
Is Gilead Sciences Stock Outperforming the S&P 500? - Yahoo Finance
Nykredit A S Makes New $177.13 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
iSAM Funds UK Ltd Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat
Gilead (NASDAQ: GILD) CEO sells 15,000 shares near $150 - Stock Titan
Gilead Sciences (NASDAQ:GILD) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Zacks Research Lifts Earnings Estimates for Gilead Sciences - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Can Bixlenvo Unlock New Growth for Gilead's HIV Business? - Yahoo Finance
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest? - Yahoo Finance
Erste Group Bank Comments on Gilead Sciences FY2026 Earnings - MarketBeat
Railway Pension Investments Ltd Sells 7,769 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ancora Advisors LLC Sells 9,072 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
FDA Approves Gilead's New Single Tablet HIV Regimen - benzinga.com
Gilead Sciences, Inc. $GILD Shares Sold by Quantitative Investment Management LLC - MarketBeat
Headlands Technologies LLC Buys Shares of 49,478 Gilead Sciences, Inc. $GILD - MarketBeat
Hennessy Advisors Inc. Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Van ECK Associates Corp Sells 488,138 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Flputnam Investment Management Co. Sells 67,582 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Wellington Management Group LLP Sells 838,308 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Nissay Asset Management Corp Japan Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Braun Stacey Associates Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Glenview Trust Co Makes New $26.78 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
United Capital Financial Advisors LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Empowered Funds LLC Acquires 30,382 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Option Exercise |
61.06 |
18,000 |
1,099,052 |
23,176 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):